In a regulatory filing, CorMedix disclosed that CEO Joseph Todisco purchased 13,561 shares of common stock for $3.74 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRMD:
- CorMedix price target lowered to $9 from $10 at RBC Capital
- Cormedix Inc.’s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient Market Adoption
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- CorMedix expects cash to fund operations for at least 12 months